Vincristine-induced vocal cord palsy and successful re-treatment in a patient with diffuse large B cell Lymphoma: a case report

BMC Research Notes

Munira Shabbir-Moosajee¹  Zarka Samoon¹ 

[1] Department of Oncology, Aga Khan University Hospital, Stadium Road, PO Box: 3500, Karachi 74800, Pakistan

关键词: Re-treatment;    Vocal cord palsy;    Vincristine;   

Others  :  1132694
DOI  :  10.1186/1756-0500-7-318

 received in 2013-12-09, accepted in 2014-05-26,  发布年份 2014

【 摘 要 】

Background

Vincristine, a type of vinca alkaloid, is widely used in the treatment of various childhood and adult malignancies. A well-known side effect of vincristine is its neurotoxicity and it is rarely indicted in vagus nerve involvement. Vincristine induced vocal cord palsy is a potentially reversible condition, with the mainstay of therapy being withdrawal of the offending drug. However, there are no clear guidelines regarding the possibility of re-treatment with the causative agent.

Case presentation

A 58 year old Asian male presented with constipation and abdominal distension. Diagnostic investigations revealed stage IVB diffuse large B cell lymphoma (DLBCL). The patient was subsequently started on R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone). On day twelve of receiving course four of R-CHOP, our patient presented to the hospital with a history of hoarseness of voice. Clinical and radiological examination revealed bilateral vocal cord palsy. Tracheostomy was done in view of a compromised airway. The patient subsequently went on to receive two more cycles of R-CHOP. Two weeks later Flexible laryngoscopy showed no lesion and the vocal cords were moving normally. The tracheostomy was removed. His voice has improved since and the patient is currently in remission.

Conclusion

The occurrence of vincristine induced vocal cord palsy has been well reported in the literature. We strongly believe that our patient developed vocal cord palsy secondary to vincristine. The uniqueness of our patient’s case lies in successful re-treatment of our patient with the offending drug. To the best of our knowledge this is the third instance where a patient was successfully re-treated with vincristine after having developed vocal cord palsy as a result of its use.

【 授权许可】

   
2014 Samoon and Shabbir-Moosajee; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Ferme C, Tilly H: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116(12):2040-2045.
• [2]Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, Lopez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011, 12(11):1013-1022.
• [3]Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 249(1):9-17.
• [4]Bradley WG, Lassman LP, Pearce GW, Walton JN: The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci 1970, 10(2):107-131.
• [5]Chan JD: Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 1998, 18(6):1304-1307.
• [6]Jeng MR, Feusner J: Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001, 18(2):137-142.
• [7]Anghelescu DL, De Armendi AJ, Thompson JW, Sillos EM, Pui CH, Sandlund JT: Vincristine-induced vocal cord paralysis in an infant. Paediatr Anaesth 2002, 12(2):168-170.
• [8]Annino DJ Jr, MacArthur CJ, Friedman EM: Vincristine-induced recurrent laryngeal nerve paralysis. Laryngoscope 1992, 102(11):1260-1262.
• [9]Tobias JD, Bozeman PM: Vincristine-induced recurrent laryngeal nerve paralysis in children. Intensive Care Med 1991, 17(5):304-305.
• [10]Latiff ZA, Kamal NA, Jahendran J, Alias H, Goh BS, Syed Zakaria SZ, Jamal R: Vincristine-induced vocal cord palsy: case report and review of the literature. J Pediatr Hematol Oncol 2010, 32(5):407-410.
• [11]Kuruvilla G, Perry S, Wilson B, El-Hakim H: The natural history of vincristine-induced laryngeal paralysis in children. Arch Otolaryngol Head Neck Surg 2009, 135(1):101-105.
• [12]Akbayram S, Akgun C, Dogan M, Sayin R, Caksen H, Oner AF: Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy. Indian J Pediatr 2010, 77(6):681-683.
• [13]Boyle FM, Wheeler HR, Shenfield GM: Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther 1996, 279(1):410-415.
• [14]Farruggia P, Tropia S, Cannella S, Bruno G, Oddo G, D'Angelo P: Vocal cord palsy after vincristine treatment in a child and the inefficacy of glutamic acid in the prevention of relapse: a case report. J Med Case Rep 2012, 6(1):128. BioMed Central Full Text
• [15]Whittaker JA, Griffith IP: Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine. Br Med J 1977, 1(6071):1251-1252.
• [16]Ahmed A, Williams D, Nicholson J: Vincristine-induced bilateral vocal cord paralysis in children. Pediatr Blood Cancer 2007, 48(2):248.
• [17]Burns BV, Shotton JC: Vocal fold palsy following vinca alkaloid treatment. J Laryngol Otol 1998, 112(5):485-487.